Kenvue reported third-quarter growth in both profit and revenue, maintaining momentum ahead of its pending acquisition by Kimberly-Clark. The over-the-counter giant’s performance highlights the sustained appeal of staple health products during periods of broader market volatility.

AbbVie shares also trended upward, buoyed by consistent demand for its immunology and neuroscience portfolios. These results were strong enough to prompt management to increase their full-year profit outlook and dividend, offering investors a rare combination of growth and reliable income.